Tommy Li

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

Martin Hutchings, Rogier Mous, Michael Roost Clausen et al. · The Lancet · 2021 · 315 citations · Full text

Subcutaneous Epcoritamab, Lymphoid Neoplasia, Dose Escalation +4

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Mallika Lala, Tommy Li, Dinesh P. de Alwis et al. · European Journal of Cancer · 2020 · 154 citations

Six-weekly Dosing Schedule, Medicine, Cancer Management +6

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With <scp>B‐Cell</scp> Lymphomas

Tommy Li, Ida H. Hiemstra, Christopher Chiu et al. · Clinical Pharmacology & Therapeutics · 2022 · 30 citations · Full text

Immunology, Pharmacotherapy, Immunotherapy +17

Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial

Arnon P. Kater, Jacob Haaber Christensen, Hans Bentzen et al. · Blood · 2021 · 22 citations

Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

Julie M. Vose, Tatyana Feldman, Martine E.D. Chamuleau et al. · Blood · 2023 · 13 citations